Suggested remit: To appraise the clinical and cost effectiveness of relugolix within its marketing authorisation for treating hormone-sensitive prostate cancer.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6187

Provisional Schedule

Committee meeting 13 June 2024

Project Team

Project lead Leena Issa

Email enquiries

External Assessment Group Southampton Health Technology Assessment Centre (SHTAC), University of Southampton


Companies sponsors Accord Healthcare Limited
Others Department of Health and Social Care
  NHS England
Patient carer groups Prostate Cancer UK
  Tackle Prostate Cancer
Professional groups Association of Cancer Physicians
  British Association of Urological Surgeons
  British Uro-Oncology Group
  Cancer Research UK
  Royal College of Physicians
  Royal College of Radiologists
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies AstraZeneca (goserelin) (confidentiality agreement not signed, not participating)
  Ferring Pharmaceuticals (degarelix, triptorelin) (confidentiality agreement not signed, not participating)
  Ipsen (triptorelin) (confidentiality agreement signed, participating)
  Neon Healthcare (buserelin) (confidentiality agreement not signed, not participating)
  Takeda (leuprorelin) (confidentiality agreement not signed, not participating)
  Typharm (leuprorelin) (confidentiality agreement not signed, not participating)
General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Institute of Cancer Research


Key events during the development of the guidance:

Date Update
01 November 2023 Invitation to participate
30 August 2023 - 27 September 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6187
23 December 2022 In progress. DHSC referral received
12 September 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual